Brookfield Asset Management Inc. Biomarin Pharmaceutical Inc Call Options Transaction History

Brookfield Asset Management Inc.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $2.86 Million - $3.57 Million	38,500 Added 34.53%	150,000 $11.6 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $6.56 Million - $8.37 Million	91,500 Added 457.5%	111,500 $9.85 Million
Q2 2021 Aug 17, 2021	SELL	$75.51 - $84.79 $1.59 Million - $1.78 Million	-21,000 Reduced 51.22%	20,000 $1.67 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $3.06 Million - $3.72 Million	41,000 New	41,000 $3.1 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.